Please login to the form below

Not currently logged in

Study sheds light on grey matter

Changes in the levels of the neurotransmitter dopamine may explain brain grey matter reductions experienced by patients with fibromyalgia, a study has found

A new brain imaging study has shown that changes in the levels of the neurotransmitter dopamine may explain brain grey matter reductions experienced by patients with fibromyalgia.

Previous research found an association between fibromyalgia and reductions in grey matter, but the cause wasn't known, say the researchers.

In this new study, Dr Patrick B Wood, of Louisiana State University Health Sciences Center, Shreveport in the US and colleagues used MRI to compare the brains of 30 women with fibromyalgia and 20 healthy women of the same age. Significant reductions in grey matter were found in the fibromyalgia patients, confirming previous findings.

The new study also found that fibromyalgia patients showed a strong correlation of dopamine metabolism levels and grey matter density in areas of the brain where dopamine is known to control neurological activity.

This association between dopamine levels and grey matter density offers new information about a possible mechanism behind some of the brain abnormalities seen in fibromyalgia patients, researchers concluded.

The study is published in the Journal of Pain (June issue).

22nd June 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...